Quote:So what can we expect when our day comes?
In spite of the difference in share structure, we have a drug with 65+ indications, not just one. So, eventually, we should eclipse the pps of GLSI.
Also worth noting that we're likely, sooner or later, to witness a dramatic short squeeze.